Cargando…
Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry
The takeover of Vectura, a healthcare company specialising in inhaled medication, by Philip Morris International raises serious ethical concerns. The European Respiratory Society notes that “health professionals will avoid prescribing drugs from any company that enriches the tobacco industry due to...
Autores principales: | Capstick, Toby G D, Hopkinson, Nicholas S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554477/ https://www.ncbi.nlm.nih.gov/pubmed/34729008 http://dx.doi.org/10.2147/COPD.S337066 |
Ejemplares similares
-
Adapting Inhaled Medication Practice in COPD and Asthma to Avoid Funding the Tobacco Industry [Corrigendum]
Publicado: (2021) -
Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms
por: Avdeev, Sergey, et al.
Publicado: (2019) -
Initial inhaler choice in COPD: real-world evidence
por: Jones, Thomas
Publicado: (2019) -
When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals
por: Gaduzo, S, et al.
Publicado: (2019) -
The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
por: Dobler, Claudia C.
Publicado: (2018)